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INTRODUCTION 
Cardiovascular disease especially AMI accounts for approximately 
12 million deaths annually and is the commonest cause of death globally. 
This problem is assuming epidemic propositions in the developing 
countries. The Asian Indians whether living in their own countries or 
elsewhere have much higher incidence of CAD as compared to all ethnic 
groups. CAD among Indians has been found to be severe, diffuse and 
associated with serious complications with increasing mortality at 
younger age. 1. 
AMI is one of the most common diagnoses in hospitalized patients 
in industrialized countries as well. In the US approximately 650,000 
patients experience a new AMI and 450,000 experience recurrent AMI 
every year. The early [30-day] mortality rate is approximately equal to 
30%, with more than half of these deaths occur before the individual 
reaches hospital and 1 in 25 patients who survives first hospitalization 
dies in the first year after AMI. Mortality is four fold in elderly patients 
[over age 75] when compare with younger age    groups.2   That is the 
magnitude of the problem.  
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The current knowledge of pathophysiology of AMI started with 
autopsy description by Dr. James Herrick from Chicago in 1912 who 
concluded that the AMI results from thrombotic occlusion of coronary 
artery and recovery depends on restoration of blood flow. In 1972 when 
coronary angiography was performed during AMI revealed that in 85-
90% patients cause of AMI was indeed thrombotic occlusion of infarct 
related artery.3 
AMI and STEMI occur when coronary blood flow decreases 
abruptly after a thrombotic occlusion of a coronary artery previously 
affected by atheroscelerosis. In most cases, AMI occurs when the 
atheroscelerotic plaque becomes disrupted [plaqgue rupture], exposing 
the contends to blood and conditions [local and systemic] favor 
thrombogenesis. 
Atherosclerosis is now proved as an inflammatory disease and 
inflammatory markers play a key role in plaque rupture and AMI. 5 An   
accumulation of clinical evidence shows markers of inflammation 
correlates with increased coronary risk. Inflammation in the vessel wall 
plays not only in the initiation and progression of atherosclerosis but also 
in the erosion or fissure of plaques and, eventually, in the rupture of 
plaques .Recent investigations have shown that various markers of 
systemic inflammation can predict future cardiovascular events including 
fatal and non fatal myocardial infarction, stroke, and the progression of 
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peripheral vascular disease in both men and women. A complex 
intravascular inflammatory response is the integral component of the 
disruption of the fibrous cap, which is the major pathophysiological event 
of the dynamic instability. 7  
In addition to hs-CRP other inflammatory markers like Total 
Leucocyte count, ESR, Free Fatty Acids were also found to be elevated 
during AMI. Vulnerable plaques have activated T cells that express 
proinflammatory cytokines such as Interferon Gamma [IFN-γ], Tumor 
necrosis factor Alpha [TNF-α], Interleukin 1 [IL-1], Interleukin 6 [IL-6]. 
During the inflammatory reaction, anti-inflammatory cytokines are also 
produced and tend to modulate the inflammatory process. IL-10 is an 
anti-inflammatory cytokine may greatly influence local inflammatory and 
thrombotic process with the atherosclerotic lesion. 
In the present work a case control study was conducted 
highlighting the elevation of hs-CRP in the blood samples of patients 
with AMI [cases] when compared with that of volunteers with no 
apparent cardiac ailment who enrolled as controls. The other 
inflammatory markers like FFA, TC, ESR along with the risk factors- 
modifiable smoking, alcohol, HT, DM, nonmodifiable- age and gender 
are compared.  
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AIM 
1. To analyze the levels of various Inflammatory markers including 
hs-CRP in Acute myocardial infarction. 
2. To correlate the variations of these inflammatory markers with 
various ECG changes of Myocardial Infarction and controls. 
3. To analyze the relationship between these markers and various 
cardiovascular risk factors 
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REVIEW OF LITERATURE 
Understanding of the pathogenesis of cardiovascular disease has 
grown significantly over the past 15 years. Evidence of the role of 
atherosclerotic plaque instability and associated intravascular thrombosis 
has revolutionized the diagnosis and management of coronary and 
cerebrovascular disease. Atherosclerotic disease begins as early as the 
second decade of life with the development of fatty streaks on previously 
normal vascular endothelium. Disease progression leads to the formation 
of nonobstructive stable atherosclerotic plaques.  
These may evolve to obstructive lesions that have the potential to 
produce symptoms such as angina, transient ischemic attacks (TIAs), or 
symptomatic peripheral vascular disease (claudication). Alternatively, 
transition of previously asymptomatic stable plaque to "vulnerable" 
plaque has the potential to result in plaque fissure or rupture, causing 
unstable angina, acute myocardial infarction, or stroke.4 Substantial 
evidence indicates that inflammation plays a significant role in the 
transition from stable to vulnerable plaque and subsequently to plaque 
injury.5 Identification of markers reflecting vascular inflammation has 
enhanced the ability to evaluate cardiovascular risk in both symptomatic 
and asymptomatic patients. C-reactive protein (CRP) is one of a number 
of markers of inflammation that has emerged a useful tool for assessing 
cardiovascular event risk.  
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Traditional Risk Factors for Coronary Artery Disease 
Traditional risk factors for coronary artery disease (CAD)) have 
been used for many years to evaluate individual patient risk and have 
been incorporated into various diagnostic and therapeutic guidelines for 
primary and secondary prevention of cardiovascular disease. The 
Framingham Risk Score utilizes several traditional risk factors to 
determine cardiovascular risk in the National Cholesterol Education 
Program's Adult Treatment Panel III report (ATP III).6  
In addition to traditional risk factors, ATP III identifies several 
nonlipid risk factors, including homocysteine; thrombogenic/hemostatic 
factors such as fibrinogen, protein C, and antithrombin III; and 
inflammatory markers including CRP, all of which have been shown to 
influence cardiovascular risk. ATP III suggests that these emerging risk 
factors may be used to adjust estimates of absolute risk obtained using 
standard risk factors. The report does not recommend routine monitoring 
of these additional risk factors, or alteration in lipid management 
strategies based on their presence.  
Many models of atherosclerosis implicate inflammation in the 
process of plaque evolution, from initiation to growth and complication, 
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such as plaque rupture. Major risk factors for atherosclerosis, including 
hypertension, hyperlipidemia, cigarette smoking, and hyperglycemia, 
provoke a variety of noxious stimuli that elicit secretion of adhesion 
molecules from leukocytes, which facilitate the attachment of monocytes 
to endothelial cells on the vasculature.7 Chemotactic factors stimulate the 
migration  of monocytes into the subintimal space.  
Monocytes are transformed into macrophages, which then take up 
cholesterol lipoproteins, becoming foam cells, and initiating the process 
of fatty streaking on the endothelial surface.8 Continued exposure to 
factors that promote lesion growth leads to accumulation of macrophages, 
mast cells, and activated T-lymphocytes within the growing plaque. The 
condition of the fibrous cap of the developing plaque is critical to the 
stability of the vascular lesion.  
A thick fibrous cap containing many smooth muscle cells, fibrin, 
and an intact endothelium covers stable atherosclerotic plaques. There are 
few inflammatory cells and the plaque core primarily contains free 
cholesterol esters within foam cells. Alternatively, the cap of vulnerable 
plaque contains eroded endothelium covering a thinner fibrous cap, which 
contains fewer smooth muscle cells and many inflammatory cells.  
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Data demonstrating that the surface temperature of vulnerable 
plaque is higher than that of stable plaque support the concept of 
inflammation.9 In addition to foam cells, the core of vulnerable plaque 
contains activated macrophages, which secrete numerous inflammatory 
substances, such as matrix metalloproteinase, responsible for eroding the 
fibrous cap. The proposed pathologic mechanisms responsible for each 
stage in the process of plaque formation and injury involve cells 
associated with the inflammatory response.  
Fissure or rupture of the fibrous cap exposes the plaque core to the 
bloodstream, instigating platelet activation, adhesion, and aggregation 
accompanied by thrombin formation leading to thrombus production and 
acute coronary or cerebrovascular events such as myocardial infarction or 
stroke. It is important to recognize that the majority of vulnerable plaques 
that produce acute coronary events such as myocardial infarction are not 
large enough to cause significant obstruction to blood flow with resultant 
exertional angina.  
Methods to identify patients with few traditional risk factors who 
remain at high risk as a result of vulnerable plaque development may 
ultimately allow for more effective treatment strategies to reduce 
cardiovascular event risk.  
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Proinflammatory Risk Factors  
Activation of the inflammatory process in both plaque 
development and in the transition to vulnerable plaque produces a number 
of molecules, which reflects ongoing inflammation. These include 
proinflammatory risk factors such as oxidized low-density lipoproteins; 
cytokines such as interleukin-1 and tumor necrosis factor alpha (TNF-
alpha); adhesion molecules such as intracellular adhesion molecule-1; and 
inflammatory stimuli, which lead to the production of acute-phase 
reactants from the liver and other sources.10  
CRP is an acute phase reactant produced by the liver and was 
initially understood to bind to complement to assist in the destruction of 
bacterial cell walls as part of the immune response to infection.11 Hepatic 
production of CRP is thought to be a response to the presence of 
interleukin-6 and other products of the inflammatory cascade. Recently it 
has been shown that CRP may be produced locally in atherosclerotic 
plaques by macrophages.12  
The role of CRP as more than a "marker" for vascular 
inflammation is supported by the knowledge that CRP within plaque 
induces the production of chemokines and adhesion molecules in a dose-
dependent fashion, attracting additional monocytes and leading to a self-
sustaining inflammatory reaction.13 
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Using CRP in Clinical Assessment of Risk  
Many products of the inflammatory cascade, in addition to CRP, 
have been shown to be markers for cardiovascular events. These include 
white blood cell count, fibrinogen, interleukin-6, plasminogen activator, 
intracellular adhesion molecules, TNF-alpha, serum amyloid A, and 
others.14 The advantages of utilizing CRP for clinical assessment of 
cardiovascular risk include assay reproducibility, standardization of 
measurement, long serum half-life, stability of basal levels over a long 
period of time, wide assay availability at reasonable cost (approximately 
$30), independence from established risk factors, and extensive data 
relative to its predictive value for future cardiovascular events.  
Many prospective epidemiological studies have established a 
relationship between CRP and future cardiovascular events including 
coronary heart disease death, myocardial infarction, cardiovascular 
events, fatal and nonfatal stroke, peripheral arterial disease, and sudden 
cardiac death.15-20 In many of these studies, CRP has been demonstrated 
to be independent of blood pressure, diabetes, smoking, age, or 
cholesterol levels.  
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Recently, Ridker et al demonstrated that CRP was a stronger 
predictor of cardiovascular events including myocardial infarction, 
ischemic stroke, coronary revascularization, or death from cardiovascular 
causes than low-density lipoprotein (LDL) cholesterol in approximately 
28,000 healthy women followed for a mean of eight years.21 CRP has 
been shown to be a stronger predictor of events than cholesterol to high-
density lipoprotein (HDL) ratio, diabetes, heart failure, or smoking 
history.22  
Among patients with known coronary artery disease, elevation of 
CRP has been associated with a 1.5-fold to twofold increase in 
cardiovascular events in patients with stable angina,23 and a 1.5- to 16-
fold increase in cardiovascular events in patients with unstable angina.24,25 
For patients who undergo percutaneous coronary intervention (PCI), 
elevated CRP levels have been shown to increase the risk of future 
restenosis and cardiovascular events twofold to 12-fold.26-27  
As might be expected from an acute-phase reactant, a single 
measurement of CRP during acute myocardial infarction is not predictive 
of future events unless the sample is taken shortly after the onset of the 
event.28Similar to measurement of LDL cholesterol in the setting of acute 
myocardial infarction, several weeks are required for the serum 
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concentration to return to baseline. Comparable to the use of traditional 
risk factors in predicting risk of future cardiovascular events, CRP is most 
useful when added to traditional risk factors, as shown by its use with the 
Framingham Risk Score.29  
Alternatively, CRP has not yet been demonstrated to be a reliable 
predictor of the extent of atherosclerotic disease when compared with 
other methods of evaluating this parameter, such as Doppler ultrasound 
scans of carotid arteries or electron beam computed tomography for 
coronary calcium.30-32  
 Atherosclerosis begins with accumulation of small lipoprotein 
molecules with arterial intima 51,53. The particles coalesce together and 
are modified and then they induce localized endothelial inflammation, 
thereby attracting leucocytes. Scavenger receptors over the surface of 
monocytes bind to modified low density lipoprotein particles, which 
transform into foam cells that become a source for further inflammatory 
cytokines.  
The level of inflammation is heightened in ruptured coronary 
plaques. Numerous inflammatory mediators such as C-RP, fibrinogen, 
IL- 18 and ICAM-1 have been proposed for risk stratification in ACS 
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patients.58,64.Using a multivariate statistical technique called Factor 
analysis, three clusters were identified; 
1. a “systemic inflammation” cluster with positive loadings of C-RP 
and  fibrinogen. 
2. a “local inflammation- endothelial dysfunction” cluster with 
positive loadings of IL- 8 and ICAM- 1  
3. an “anti-inflammation”cluster comprising IL-10 and HDL 
Cholesterol 52, 55, 78. 
Atheromatous plaque vulnerability is an important mechanism 
underlying acute coronary syndrome. Plaque destabilized by MMP- 9 and 
interferon gamma produced in response to inflammation participates in 
the mechanism of acute coronary syndrome.67 
The composition of atheromatous plaque rather than the degree of 
stenosis is now recognized as a pivotal feature in determining the plaque 
vulnerability and hence the risk of acute coronary events.36, 51, 69 
There is a current interest in the association of circulating 
inflammatory markers like C-RP, fibrinogen, white cell count, ESR, 
albumin, factor 8- VWF complex, tissue plasminogen activator: 
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plasminogen activator inhibitor type 1 complex and fibrin D-dimer not 
only with prognosis in ACS and acute stroke, but also in prediction of 
cardiovascular events.73,77 
 Activation of several neurohormonal systems occurs during AMI 
and is associated with short and long term outcomes. Renin and 
natriuretic cardiac peptides appeared to be strong predictors of outcome 
in patients with AMI. Recent research indicates that Albumin Excretion 
Rate is a powerful prediction of in-hospital and 3 year mortality in 
patients with AMI.38 
Patients with unstable angina exhibit increased levels of 
inflammatory markers like IL- 6, SVCAM-1 and VWF but decreased 
levels of thrombotic markers like AT- III and protein- C whereas patients 
with AMI show higher levels of inflammatory as well as thrombotic/ 
fibrinolytic markers 39, 48, 76 
          There exists a difference between inflammatory and thrombotic 
markers between UA and AMI. In acute phase and in a follow up of ACS, 
abnormal coagulation, inflammation and fibrinolytic markers have 
independent and direct relationship with cardiovascular adverse events.49. 
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           Other interesting finding -for its accessibility-in acute myocardial 
infarction under coronary percutaneous intervention is persistent ST 
elevation, leucocytes and fibrinogen predictive value.61 
 In consideration of the important role that inflammatory processes 
play in determining plaque stability, recent work has focused on whether 
plasma markers of inflammation may help improve risk stratification. Of 
these markers, C- RP has been the most widely studied. Even among 
patients with Troponin negative ACS, elevated levels of C-RP are 
predictors of future risk.42 
 C-RP formerly considered solely an excellent biomarker of 
inflammation , is now viewed as a direct contributor in atherosclerosis.44 
With the advent of high sensitive assays for determining C-RP , this 
protein has emerged as one of the most powerful independent predictors 
of cardiovascular events. 
 Levels of C-RP and IL-6 are elevated in patients with UA and 
myocardial infarction, with high levels predicting worse prognosis. 33, 37,63 
In people with ACS, hs-CRP measurement may be valuable. 
Elevated levels in the highest quartile seem to predict greater mortality 
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and poorer prognosis in patients with unstable angina and myocardial 
infarction.62, 66. 
Research has focused on inflammatory, lipid and metabolic profile 
in ACS and correlated with hospital and post hospital events21. It is found 
that increased hs- CRP and altered glycemia are associated with a greater 
number of hospital events whereas age, previous AMI , AMI with or 
without ST elevation and altered glycemia are predictors of hospital 
mortality. 
Recent evidences have emerged implicating C-RP directly in 
atherogenesis.80, 82, 83  C-RP has been found in human atherosclerotic 
plaque and C-RP has been shown to cause endothelial cell dysfunction, 
oxidant stress and intimal hypertrophy in experimental models. 
In severe acute coronary syndromes elevations of markers of 
inflammation and acute phase reactant like C-RP as well as release of 
troponins have been reported.48, 81. 
It must be stressed that C-RP, because of its analytical and 
biological properties and the large amount of available data, is the only 
inflammatory marker accepted for clinical use.40, 54, 56 
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The hs-CRP not only predicts future cardiovascular events but also 
can be used to target therapeutic interventions.39,43,71 Levels of hs-CRP <1 
,1-3 and >3 mg/L correspond to lower, moderate and higher risk of 
cardiovascular events at all levels of Framingham Risk Score and at all 
levels of metabolic  syndrome.68,72. 
Interventions that lower hs-CRP include diet, exercise, smoking 
cessation, statin therapy and improved glycemic control and when a PCI 
is necessary, provisional stenting.79 
In the setting of AMI, elevated C-RP levels may reflect the 
inflammatory activity of a ruptured plaque.34, 60, 75 
C-RP levels and neutrophil count are higher in angina patients with 
coronary stenoses. Compared to those without neutrophil  count, but not 
C-RP levels, correlates with angiographic stenoses complexity.35 
Experiments in rats have shown that a molecule called 1,6- bis 
(phosphocholine) –hexane inhibits C-RP and thereby limits the size of 
infarction. In addition, the availability of a C-RP inhibitor will facilitate 
experiments to determine the role of human C-RP in normal biological 
processes and disease states including atherogenesis, plaque instability, 
stroke, infection, inflammatory diseases and autoimmunity.71 
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C-REACTIVE PROTEIN 
HISTORY AND NOMENCLATURE 
C-RP was originally discovered by Tillett and Francis in 1930 as a 
substance in the serum of patients with acute inflammation that reacted 
with C-polysaccharide of pnuemococcus. 
GENETICS AND BIOCHEMISTRY                
The  C-RP  gene is located on the first chromosome (1q21-q23).  
C-RP is a 224 residue protein with a monomer molar mass of 25106 Da 
and native cyclic pentamer mass of 125530. 
FUNCTION 
C-RP is a member of the class of acute phase reactants. It is 
thought to assist in complement binding to foreign and damaged cells and 
affect the humoral response to disease. It is also believed to play an 
important role in innate immunity, as an early defense system against 
infection. 
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DIAGNOSTIC USE 
C-RP is used mainly as a marker of inflammation. Measuring and 
charting C-RP values can prove useful in determining disease processes 
or the effectiveness of treatment. 
C-RP AND ATHEROSCLEROSIS 
           Accumulating  data  suggest  that  arterial   tissue   can   produce 
C-RP,with C-RP and complement m-RNA being substantially up-
regulated in atherosclerotic plaque 45. Thus C-RP may serve as an 
endogenous activator of complement in atheroma. 
DYNAMICS OF C-RP 
The acute phase response comprises the non-specific physiological 
and biochemical responses of endothermic animals to most forms of 
tissue damage, infection, inflammation and neoplasia. In particular, the 
synthesis of a number of proteins is rapidly up-regulated principally in 
hepatocytes, under the control of a cascade of cytokines, including 
interleukins-1, tumour necrosis factor-alpha and interleukins-6, 
originating at the site of pathology. 
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 C-RP levels rapidly rise after an inflammatory stimulus and 
depending on the intensity of the stimulus, even a several-hundred-fold 
increase in plasma levels may occur41. C-RP is not consumed to a 
significant extent in any process and its clearance is not influenced by any 
known condition. Therefore its concentration appears to be dependent 
only on the rates of production and excretion. The long half life of C-RP, 
approximately 19 hours, makes its detection in blood easy even several 
hours after acute stimulus. Because of all these characters. C-RP can be 
called as an “ideal marker of inflammation.”                                      
ERYTHROCYTE SEDIMENTATION RATE (ESR) 
ESR is a non specific inflammatory marker discovered much 
before C-RP. It is primarily based on changes in aggregation (roulette 
formation or piling) tendency of red blood cells. ESR depends on 
concentration of positively charged serum proteins such as fibrinogen and 
immunoglobulins, with increased concentrations neutralizing the net 
negative charge (zeta potential) of red blood cells. 
ESR is a complex phenomenon depending not only on the 
inflammatory condition but also on red cell density, plasma viscosity; red 
cell morphology and hemoglobin content.57 Reference values for ESR 
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differ according to sex and age and are also influenced by pregnancy and 
obesity. 
ESR rises in conditions of myocardial damage and necrosis in the 
order of 15-40 mm/hr Normal reference range: 
Males- 0 to 17 mm/hr 
Females – 1 to 25 mm/hr 
LEUCOCYTE COUNT 
Epidemiologic studies have demonstrated correlations between the 
white blood cell count and the risk of acute myocardial infarction and 
stroke. The risk of AMI is approximately four times greater in persons 
with WBC counts high in the normal range (>9,000/ml) than in persons 
with WBC counts low in the normal range (<6,000/ml). A high WBC 
count also predicts a greater risk of re-infarction and of in-hospital death. 
In the last decade it has become evident that the pathogenesis of 
atherosclerosis involves several complex mechanisms; these include the 
immune system, the inflammatory response, and the infectious etiologies. 
We would like to focus on the role of the white blood cell in 
atherogenesis, atherothrombosis, and the risk of developing AMI and its 
complications.92 
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Epidemiologic observations 
In 1974, Friedman et al. reviewed 464 patients who had suffered a 
first AMI and whose WBC count had been measured in the preceding 2 
years. These patients were compared with two control groups: one was 
matched for age, gender and race, and the other for these variables and 
for conventionally recognized risk factors for infarction. It was found that 
the WBC count was a strong predictor of infarction. The predictive value 
of the WBC count was similar to that of a serum total cholesterol 
measurement or a single determination of blood pressure.  
The height of the WBC count correlated positively with tobacco 
smoking, but only about two-thirds of the predictive value of the WBC 
count could be explained on the basis of this observation. In another 
study 7,000 males were followed for an average of 6.5 years. Among 
smokers, the WBC count correlated strongly with the risk of AMI. 
Smokers with WBC counts exceeding 9,000/ml had an incidence of AMI 
four times higher than in smokers with a leukocyte count below 6,000/ml, 
a difference that was statistically significant.93  
In the Hiroshima/Nagasaki survivors' surveillance, the WBC count 
correlated significantly with the incidence of coronary heart disease. That 
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is, a total WBC count in excess of 10,000/ml was associated with a risk 
that was approximately twice that seen when the WBC count was at or 
below 4,000/ml. This excess risk was independent of gender, smoking 
history, blood pressure, and cholesterol level. 
Examination of differential cell counts showed the strongest 
association to be with the neutrophil count. It has been shown (also in the 
Hiroshima/Nagasaki survivors' surveillance) that total WBC count was 
correlated with the risk of thrombotic cerebral infarction; the 469 patients 
suffering thrombotic strokes had a statistically significantly higher 
antecedent WBC count than did members of the cohort not experiencing 
ischemic events.94 [7].  
Again, the examination of differential WBC counts showed a 
statistically significant predictive power only for neutrophils. A strong 
independent correlation was found in the Multiple Risk Factor 
Intervention Trial (MRFIT) between total WBC count and the risk of 
coronary heart disease.95 Even when tobacco smoking was 
controlled/corrected for, the WBC count was found to predict coronary 
heart disease prevalence, risk of non-fatal MI, and risk of sudden cardiac 
death. Moreover, if the WBC count declined during the period of 
surveillance, so did the CHD risk: a decrement of 1,000 WBC/ml was 
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associated with a 14% decrement in risk of cardiac death, unexplainable 
by changes in other cardiac risk factors.  
In the PARIS-1 study, 2,026 patients were examined 2±60 months 
after suffering a first AMI; the total WBC count obtained at that time was 
found to correlate strongly with risk of re-infarction. Men with WBC 
counts exceeding 9,000/ml had a relative risk of re-infarction of 3.5, 
when 1.0 was set equal to the risk for men with WBC counts at or below 
5,000/ml. An elevated leucocyte count is an epidemiological marker for 
coronary heart diseases. 
Acute myocardial infarction is usually accompanied by 
leucocytosis which is related to the magnitude of necrotic process, 
elevated glucocorticoid levels and possibly inflammation in coronary 
arteries. The magnitude of elevation of leucocyte count is associated with 
in-hospital mortality 47,68Activation of neutrophils may produce important 
intermediaries such as LT-B4 and oxygen free radicals that have 
important micro circulatory effects. Neutrophilic leucocytosis in the order 
of 12000 to 15000 cells/cu.mm occurs in acute myocardial infarction. 
 Normal reference range: 4.5 to 11.0 X 10 3 Cells /cu.mm 
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HIGH SENSITIVE C-RP 
C-RP molecule itself is not a harmful molecule in the body. The 
higher level of C-RP is simply a reflection of higher than normal 
inflammation. The measurement of C-RP does not reflect where the 
inflammation is. It may come from cells in the fatty deposits in arterial 
walls that reflects the process of atherosclerosis. It may come from other 
tissues. 
 The time honoured semi-quantitative immunoassay for serum C-
RP employs a polyclonal antibody to detect gross elevations in acute 
inflammatory illness. This rise remains stable over a period of several 
days in vivo and the protein is resistant to in vitro degradation. 
Conventional flocculation assays used for C-RP measurement in acute or 
chronic inflammatory illness detect only gross elevations. This test is now 
being phased out. 
 The monoclonal antibody based hs-CRP enzyme immunoassay or 
its automatable rapid counterpart the monoclonal polystyrene 
microparticle assay, however may detect normal or slightly elevated 
serum C-RP concentrations. Consequently, hs-CRP is recommended as a 
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clinical tool to evaluate low level systemic inflammation and thus to 
predict cardiovascular diseses30. 
Normal reference range:  0.02 to 8.0 mg/L 
FREE FATTY ACIDS 
Serum concentrations of free fatty acids (FFA) have been shown to 
be raised in patients with acute myocardial infraction. In other studies 
several authors have suggested a positive relationship between serum 
FFA and complicating arrhythmias and death after myocardial 
infarction.86, 88, 89 They were of the opinion that high circulating FFA 
levels, were associated with intracellular lipid disturbances which could 
in turn provoke the arrhythmias. Various authors considered that the lipid 
changes were merely coincidental and elevation of serum FFA may be 
due to other metabolic events such as increased catecholamine secretions 
or starvation. 90, 91 
Normal reference range: < 8-25mg/dl 
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MATERIALS AND METHODS 
STUDY DESIGN: 
 A case control study conducted in Intensive Coronary Care 
Unit(ICCU) at Govt. Kilpauk Medical College, Chennai 600 010. 
 DURATION OF STUDY 
January 2008 – August 2008  
INCLUSION CRITERIA 
CASES  
Patients presenting with acute myocardial infarction (AMI) with 
acute ECG changes within 12 hrs of the onset of chest pain 
CONTROLS 
50 volunteers without any apparent cardiac ailment 
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EXCLUSION CRITERIA 
1. Intercurrent inflammatory or neoplastic conditions likely to 
present with acute phase response by clinical evaluation. 
2. Surgery, trauma in the preceding six months. 
3. Presence of connective tissue disorders like SLE, Rheumatoid 
arthritis and other collagen vascular diseases 
4. Inflammatory bowl disorders, pancreatitis  
5. Hepatic failure 
6. Renal failure 
7. Heart failure     8. Cerebrovascular Accident 
STUDY POPULATION 
In our study a total of 100 patients were enrolled. Of which 50 
patients presented with AMI and with acute changes in ECGs within 12 hrs 
of onset of chest pain were enrolled as cases. Patients were admitted to the 
intensive coronary care unit [ICCU] of Department of Cardiology Govt  
Kilpauk medical college Chennai-10. The age ranges from 30 to 85 and 
study included   both sexes.  
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 In the control group 50 healthy volunteers were included. They 
had no past history or evidence of cardiovascular diseases. None of the 
control subjects gave history of neoplastic, hepatic, infectious or 
autoimmune diseases or any surgical procedure in the preceding six months.  
The study was approved by institutional ethics committee.                       
Detailed history recorded from the patients with reference to the features of 
the chest pain, location, radiation, aggravating and reliving factors, increase 
autonomic activity and other clinical features suggestive of acute myocardial 
infarction (AMI). The diagnosis of myocardial infarction was based on 
clinical and electrographic evidence using the criteria recommended by 
W.H.O.101  
The other conditions which are likely to induce acute phase reactants 
were carefully ruled out by detailed history taking and thorough clinical 
evaluation. The risk factors associated with, both modifiable like cigarette 
smoking, alcohol consumption, hypertension, diabetes mellitus and obesity 
(BMI) and non- modifiable like age, sex, family history were taken into 
consideration. Cases were grouped as per their age, BMI, sex and diagnosis 
and compared with controls.  
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 At the onset standard 12 lead ECG was taken and blood sample 
was collected for routine investigations, and for acute phase reactants hs- 
CRP (highly sensitive C – reactive protein ), FFA.  Early morning blood 
sample was collected for ESR and Lipid Profile. The diagnosis is made 
by internationally accepted criteria recommended by WHO. 
 All the patients were thrombolysed and standard treatment 
guidelines were followed. The Inflammatory markers were studied for 
variations among 50 patients admitted in the ICCU of Govt Kilpauk 
Medical College with AMI and with acute ECG changes (cases) and 50 
healthy volunteers with no apparent cardiac ailment who were enrolled as 
controls. The groups cases and controls were compared for Age 
distribution, Sex, BP,BMI and Lipid Profile to find out statistical 
significance. 
 The Inflammatory markers hs-CRP, TC, ESR, FFA in cases and 
controls were analyzed for statistical variance. 
  The risk factors smoking and alcohol were found out by careful 
history taking. The risk factors DM and HT were detected by past 
medical history and laboratory routine investigation and BP 
measurement. These risk factors were studied for statistical correlation 
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between cases and controls first. Then the Inflammatory markers were 
analyzed for statistical variations with risk factors smoking and alcohol 
followed by risk factors DM and HT. The statistical correlation between 
the Inflammatory Markers and the various changes of ECG in our study 
group was also studied. 
MATERIALS 
Questionnaire, 
BMI calculation, 
Blood pressure,  
Blood Total WBC count  
Erythrocyte Sedimentation Rate  
Total Cholesterol, 
Triglycerides, 
HDL 
 LDL 
hs-CRP 
Free Fatty Acids.  
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BMI CALAULATION 
Body mass index is calculated with height and weight of the 
subject using the following formula. 
BMI= weight (kg) / height(m)2 
Normal 20- 25 kg/m2 
Over Weight > 25-30 kg/m2 
Obese > 30kg/m2 
 BLOOD PRESSURE 
  Right upper arm blood pressure is taken in supine position by using 
sphygmomanometer under appropriate condition. 
 hs-CRP 
Blood samples are collected from patients and tested in a private 
laboratory by Latex turbimetry method. 
Total count 
Blood samples are collected and estimated in Kilpauk Medical 
College Laboratory. 
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E S R 
Calculated by Westegran’s method. 
Lipid Profile 
Lipid profile is done for all the subjects in fasting blood sample. 
Blood samples were collected in early morning with over night fasting. 
Total Cholesterol 
Calculated by CHOD-PAP method. 
Triglycerides 
Calculated by GPO-pap method. 
H D L 
Calculated by HDLc-p precipitating method. 
LDL  
Calculated by Friedwald Formula 
LDL cholesterol = Total cholesterol–[Triglyceride/5 – HDL 
cholesterol]. 
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FFA 
Calculated manually in a private laboratory. 
STATISTICAL ANALYSIS:  
Descriptive statistics mean and standard deviation was used to 
summarize normally distributed continuous variables.  All statistical 
analysis was done using SPSS (Statistical Package for Social 
Sciences) v 1.5.  A p value of less than 0.05 was considered 
statistically significant. 
• Students two sample test was used to compare two variables. 
• Chi square test was used to analyze descriptive variables. 
• Anova test was used to compare multiple variables 
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RESULTS AND ANALYSIS 
• A total of 50 patients admitted in the ICCU within 12 hrs of 
onset of chest pain and with acute ECG changes were enrolled 
as cases. 
• A total of 50 volunteers with no cardiac abnormality were 
enrolled as controls. 
• Mean age of cases was 53.30 ± 12.21 years. 
• Mean age of controls was 48.7 ± 7 years.  
• Statistically significant difference was noticed among cases and 
controls with regard to age. P value 0.027. 
• Statistically significant difference was noticed among cases and 
controls   with regard to sex. P value  0.000. 
• In our study male gender predominance is observed with regard 
to AMI.     
•  Mean BMI of cases was 24.44 ± 4.49 kg/m². 
• Mean BMI of controls was 26.996 ± 4.46 kg/m². 
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• Statistically significant difference was noticed among cases and 
controls with regard to BMI. P value 0.005.  
• Statistically significant difference was noticed among cases and 
controls with regard to BP. 
• Mean systolic BP for cases and controls were 135.76 ±28.31 
and 124.4 ± 12.33. P value o.011 
• Mean diastolic BP for cases and controls were 90.2 ± 16.84 and 
82.72± 8.16. P value 0.006 
• AMI had a significant correlation with high BP 
• In Lipid profile TGI and HDL showed statistically significant 
difference. while Total Cholesterol and LDL did not show any 
significance 
• P value for TGL was 0.000   
• P value for HDL was 0.041   
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• Statistically significant difference was noticed among cases and 
controls with regard to risk factors smoking and alcohol. More 
occurrence of AMI among smokers and alcoholics in our study.     
P value 0.004. 
• The risk factors DM and Hypertension did not show any 
statistical significance. 
• Among the inflammatory markers studied only hs-CRP vary 
with statistical significance. P value 0.000. 
• TC, ESR, FFA values did not show any statistical significance. 
• The inflammatory profile did not show any statistical 
significance with regard to risk factors smoking and alcohol. 
• Except ESR no other inflammatory markers did show any 
statistical significance with regard to risk factors DM and HT. 
• P value for ESR when studied with risk factor DM and HT was 
0.014  
• Among the Inflammatory profile markers studied on 
comparison with various ECG changes hs-CRP and ESR 
showed statistically significant variation while TC and FFA did 
not show any significance 
     P value for hs-CRP was 0.000 
     P value for ESR was 0.031. 
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TABLES AND VALUES  
AGE DISTRIBUTION ANALYSIS 
TABLE 1 
GROUP NO MEAN AGE STD DEVIATION
CASE 50 53.3 12.21
CONTROL 50 48.7 7.799  
Mean age of cases was 53.30 ± 12.21 years.   
Mean age of controls was 48.7 ± 7 years.  
TABLE  2 
AGE GROUP (Years) CASE CONTROL
30-35 8 9
36-40 9 10
41-45 4 11
46-50 8 9
51-55 8 9
>56 13 2  
   P = 0.027 SIGNIFICANT 
Statistically significant difference was noticed among cases and 
controls with regard to age.  
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SEX DISTRIBUTION ANSLYSIS 
TABLE 3 
SEX CASE CONTROL
MALE 40 23
FEMALE 10 27  
P VALUE 0.000 SIGNIFICANT 
Statistically significant difference was noticed among cases and 
controls with regard to sex. 
SEX
2.001.00
C
ou
nt
50
40
30
20
10
0
GROUP
    1.00
    2.00
 
In our study male gender predominance is observed with regard to 
occurrence of AMI. 
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BMI 
TABLE 4 
GROUP NO MEAN SD
CASE 50 24.44 4.49
CONTROL 50 26.996 4.46  
Mean BMI of cases was 24.44 ± 4.49 kg/m². 
Mean BMI of controls was 26.996 ± 4.46 kg/m². 
TABLE 5 
BMI GROUP CASE CONTROL
<25 28 19
25-30 13 18
>31 9 13  
P = 0.005 SIGNIFICANT 
Statistically significant difference was noticed among cases and 
controls with regard to BMI. 
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BLOOD PRESSURE 
TABLE 6 
BP VALUES CASE CONTROL
SYSTOLE MEAN ± SD 135.76 ± 28.31 124.40 ± 12.33
DIASTOLE MAEN ± SD 90.20 ± 16.84 82.72 ± 8.16  
P VALUE for SYSTOLIC BP was   0.011    SIGNIFICANT 
P VALUE for DIASTOLIC BP was 0.006   SIGNIFICANT 
Statistically significant difference was noticed among cases and 
controls with regard to BP. 
LIPID PROFILE 
TABLE 7 
NO TGL CHOLESTEROL HDL LDL
CASE
CONTROL
50
50 184.02 ± 33.43 44.98 ± 4.87
210 ± 58.74
159 ± 77.23
110.64 ± 31.99
107.4 ± 33.06
42.46 ± 7.1192.4 ± 44.86
 
P VALUE for TGL was 0.000   SIGNIFICANT 
P VALUE for HDL was   0.041   SIGNIFICANT 
P VALUE for CHOLESTEROL was 0.292   NOT SIGNIFICANT  
P VALUE for LDL was 0.62    NOT SIGNIFICANT 
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In Lipid profile TGI and HDL showed statistically significant 
difference while Total Cholesterol and LDL did not show any 
significance. 
RISK FACTORS - SMOKING AND ALCOHOL 
TABLE 8 
SMOKING & 
ALCOHOL CASES CONTROLS
NIL 14 32
SMOKING 12 6
ALCOHOL 3 1
BOTH 21 11  
P  VALUE 0.004   SIGNIFICANT 
Statistically significant difference was noticed among cases and 
controls with regard to risk factors smoking and alcohol. More 
occurrence of AMI among smokers and alcoholics in our study. 
RISK FACTORS - DM AND HT 
TABLE 9 
DM & HT CASE CONTRTOL
NIL 14 20
DM 13 5
HTN 15 13
BOTH 8 12  
P  VALUE 0.135 NOT SIGNIFICANT 
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The risk factors DM and Hypertension did not show any statistical 
significance. 
INFLAMMATORY PROFILE 
TABLE 10 
NO hs- CRP TC ESR FFA
50 4.31 ± 4 9628 ± 894.19
3.34 ± 2.97
18.36 ± 14.84
10424 ± 2816.46 21.24 ± 21.97
CASE
50
CONTROL
9.31 ± 2.36
3.5 ± 3.09
 
P VALUE for hs- CRP was 0.000   SIGNIFICANT 
P VALUE for TC was 0.134   NOT SIGNIFICANT 
P VALUE for ESR was 0.444   NOT SIGNIFICANT 
FFA P VALUE for FFA was 0.787   NOT SIGNIFICANT 
Among the inflammatory markers studied only hs-CRP vary with 
statistical significance. 
TC, ESR, FFA values did not show any statistical significance. 
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INFLAMMATORY PROFILE VS RISK FACTORS 
SMOKING AND ALCOHOL 
TABLE 11 
RISK FACTOR N0 hs-CRP TC ESR FFA
46NIL
SMOKING
ALCOHOL
BOTH 32
5.9 ± 4.68
7.18 ± 3.64
8.025 ± 4.69
7.706 ± 3.29
18
4
1O896.88 ± 2816.37
1O575 ± 315.71
9427.8 ± 713.89
9682.6 ± 2253.6 3.28 ± 2.88
3.92 ± 3.88
4.225± 2.79
3.24 ± 2.76
17.57 ± 6.08
16.17 ± 16.60
13 ± 3.46
25.91 ± 23.04
 
P VALUE for  hs-CRP     was  0.256 NOT SIGNIFICANT 
P VALUE  for TC was 0.093   NOT SIGNIFICANT 
P VALUE for ESR was 0.152   NOT SIGNIFICANT 
P VALUE for was FFA 0.803   NOT SIGNIFICANT 
The inflammatory profile did not show any statistical significance 
with regard to risk factors smoking and alcohol 
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INFLAMMATORY PROFILE VS RISK FACTORS 
DM AND HT 
TABLE 12 
RISK 
FACTOR NO hs-CRP TC ESR FFA
11100 ± 3391.16
7.09 ± 4
6.92 ± 3.68
8.5 ± 4.32 3.60 ± 3.08
12.53 ± 9.36
20.72 ± 20.61
21.39 ± 18.5
29.1 ± 24.81
5.57 ± 4.185 2.8 ± 2.45
3.5 ± 3.68
3.996 ± 3.15
9417.65 ± 1521.46
10044.44 ± 2735.87
10110.71 ± 2106.49
34
18
28
20
NIL
DM
HTN
BOTH
 
P VALUE for ESR was 0.014   SIGNIFICANT 
P VALUE for hs-CRP was   0.085  NOT SIGNIFICANT 
P VALUE for TC was  0.104   NOT SIGNIFICANT 
P VALUE for FFA was 0.471   NOT SIGNIFICANT 
Except ESR no other inflammatory markers did show any 
statistical significance with regard to risk factors DM and HT. 
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INFLAMMATORY PROFILE VS ECG CHANGES 
TABLE 13 
ECG NO hs- CRP TC ESR FFA
EXTENSIVE 
AWMI
51
29
16
1
NORMAL
AWMI
IWMI
BOTH
3 9.43 ± 1.25
4.43 ± 4.05
9.42 ± 2.58
9.19 ± 2.29
8
9433.33 ± 472.58
18.16 ± 14.76
16.51±15.9
33.06 ± 29.48
20
8.67 ± 2.3
9684.31±1877.698
9920.69 ± 2349.53
11650 ± 3623.26
9800
8.67 ± 2.30
3.44 ± 3.089
3.39 ± 3.41
3.39 ± 2.09
2.3
 
   P VALUE FOR ECG CHANGES VS hs-CRP < 0.001 
   P VALUE FOR ECG CHANGES VS ESR 0.031 
   P VALUE FOR ECG CHANGES VS TC 0.072 
   P VALUE FOR ECG CHANGES VS FFA 0.0995 
Among the Inflammatory profile markers studied on comparison 
with various ECG changes hs-CRP and ESR showed statistically 
significant variation while TC and FFA did not show any significance. 
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DISCUSSION 
  A case control study was carried out in our present study in which 
50 patients with AMI with acute ECG changes were enrolled as cases and 
50 volunteers with clinically no apparent cardiac aliment were enrolled as 
controls. 
The inflammatory markers hs-CRP , TC, ESR and FFA levels n the 
cases were compared with that of controls along with modifiable risk 
factors like cigarette smoking, alcohol, HT, DM and non – modifiable 
risk factors like age and gender. 
AGE 
The mean age for the cases (Mean ± SD) was 53.3 ± 12.21 years 
and for controls (Mean ±SD) was 48.7 ± 7.799 years. A statistically 
significant difference with regard to age (P= 0.027) was observed. 
This is inconsistent with the study conducted by Arunkumar99 et al 
where the age (Mean ± SD) for cases and controls were 61.84± 3.80 vs 
60.55± 3.98 with P=0.0037 respectively. 
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SEX 
In our present study among the cases 80 % were males (40/50) and 
20% (10/50) were females in controls 46% (23/50) were males and 54% 
(27/50) were females. As per this a statistically significant difference was 
present (P=0.000) with regard to sex and hence a male gender 
predominance. 
This is in consistent with the study conducted by Arunkumar99et al, 
where among the 165 patients enrolled as cases 123 were males and 42 
were females, while the controls and the same member of male and 
female volunteers, with statistically significant variation with regard to 
sex (P<0.05) and male gender predominance. 
BMI 
In the present study cases and controls were grouped into three 
categories according to BMI. 56% (28/50) were normal weight, 20% 
(13/50) were over weight and 18% (9/50) were obese in the cases. 
Among the control 38% (19/50) were of normal weight. 36% (18/50) 
were of over weight, 26% (13/50) were obese. 
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The mean BMI (Mean ± SD) for cases and controls were 24.43 ± 
4.49 vs 26.996 ± 4.457 respectively. A statistically significant difference 
observed with regard to BMI in this study (P=0.005). 
This is in consistent with the study conducted by Arunkumar99 et al 
the BMI values  (Mean ± SD) for cases and controls were 26.16 ± 1.45 vs 
25.40 ± 1.20 respectively with P<0.01. 
LIPID PROFILE 
In our present study the lipid profile was compared between cases 
and controls. The values for TGL and HDL vary with statistical 
significance between the groups, while the values for total cholesterol and 
LDL did not show any significance. The values (Mean ± SD) for TGL for 
cases and controls were 210.16 ± 58.74 vs 159 ± 77.23, with P values 
0.000.The values (Mean ± SD) for HDL were 42.46 ± 7.10 vs 44.98 ± 
4.87 for cases and controls respectively with P values 0.041.  
This is inconsistent with the study conducted by Arunkumar99 et al 
where the TGL values (Mean ± SD)  for cases and controls were 128.96 ± 
12.19 vs 107.84 ± 11.51 with statistically significant difference (P< 
0.001). 
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This is in contrast to the study conducted by Srikanth K. 
Sivaraman96 et al where elevated levels of Total Cholesterol in patients 
with AMI (Mean ± SD)    when compared with cases. The values were 
199.76 ± 18.82 vs 168.75 ± 14.64 with statistical significance 
(P<0.001).While the values of TGL, HDL, LDL were not altered much 
when compared to controls. 
In contrast to the present study, the study conducted by 
Arunkumar99 et al showed statistical significance with regard to LDL. In 
our study the values for LDL (Mean ± SD)     for cases and controls were 
110.64± 31.995 vs 107.40 ± 33.062 respectively (P=0.62). The values in 
the study conducted by Arunkumar et al for cases and controls were 
119.37 ± 14.05 vs 83.59 ± 11.95 with significant correlation with regard 
to LDL (P<0.001). 
BLOOD PRESSURE 
In the present study blood pressure systolic and diastolic found to 
show significant correlation between cases and controls. 
The systolic BP values (Mean ± SD) for cases and controls were 
135.76 ± 28.31 vs 124.40 ± 12.33 with P value 0.001, and diastolic BP 
values (Mean ± SD) for cases and controls were 90.20 ± 16.84 vs 82.72 ± 
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8.16 with the P values 0.006.So as per our study  there was a correlation 
between high BP and AMI. 
This is in consistent with the study conducted by Arunkumar 99et al 
where the values for systolic BP (Mean ± SD) for cases and controls were 
136 ± 23 vs 113 ± 8 with P < 0.02, and diastolic BP values (Mean ± SD) 
for cases and controls were 95 ± 10 vs 85 ± 7 with the P < 0.02. 
RISK FACTORS 
In our present study statistically significant correlation observed 
between AMI and risk factors smoking and alcohol (P=0.004). The risk 
factors DM and HT showed no significant correlation. 
INFLAMMATORY PROFILE 
Out of 50 patients in the cases, 43 were found to be with elevated 
hs-CRP. In the controls 7 volunteers without any apparent cardiac ailment 
were found with elevated hs-CRP. On comparing these two groups 
statistically significant difference was noted in hs-CRP levels. The values 
(Mean ± SD) for cases and controls were 9.308 ± 2.35 mg/L vs 4.31 ± 
4.007 mg/L with highly significant P values (P=0.000). This is in 
consistent with various other studies. 
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A study conducted by Sreekanth L. Sivaraman 99et al  in 2004 CRP 
levels were elevated in AMI (40.8± 15.4 mg/L) when  compare to 
controls with normal heart ( 12.6± 2.8 mg/L).There was a statistically 
significant difference between cases and controls with P values<0.001. 
In a study conducted by A.L. Pasqui102 et al in 2005 hs-CRP levels 
in AMI was 4.3 ± 2.8 and for controls was 1.2 ± 0.4. A statistically 
significant difference observed in this study (P<0.01). 
In a study conducted by Dr.Arunkumar99et al (Pak.J.Med. Sci.) in 
2002-2006 higher plasma levels of CRP was found in Pts with AMI when 
compare to control. The CRP levels for controls 1.12± 0.33 while for the 
patients with AMI it was  2.97 ± 1.11 .This was statistically significant 
with P= <0.001. 
 In a study conducted by YIP HK, 100 Wu CJ, Chang HW et al 
(CRP 3) Serum levels of hs-CRP was significantly higher in patients with 
an onset of MI <6 hrs when compared to healthy subjects. (2.7 ± 2.3 
mg/L vs 1.0 ± 0.6 mg/L with P<0.0001). 
53 
 
In the present study TC was not found to be statistically significant. 
The values for TC (Mean ± SD) for cases and controls was (10424.00 ± 
2816.46 vs 9698.00 ± 1894.19) with P values 0.134. The ESR was also 
not found to be varying significantly when AMI patients were compared 
with controls in our present study. The values for ESR (Mean ± SD) for 
cases and controls in our study were 21.24 ± 21.97 vs 18.36 ± 18.84 
respectively. 
This is in contrast to a study conducted by Srikanth K. Sivaraman97 
et al. There the values for total WBC count and ESR varied significantly 
with controls. The values for ESR in patients with MI compared with 
controls was 55.2  ± 28.0 vs 25.2  ± 10.3 ,and for total WBC count the 
values were 11480.8  ± 4345 vs 8949.6  ± 1853. The P values for both 
were <0.01. 
 In our present study the inflammatory markers FFA levels in AMI 
patients was compared with that of controls. No significant difference 
observed in this study. The values for cases and controls (Mean ± SD)   
were 3.34 ± 2.97 vs 3.50 ± 3.09 with P values of 0.181. This was in 
contrast to  the study conducted by V.S. Singh 98 S.Kirti et al. Where 
serum FFA have been shown to be raised with AMI with statistical 
significance. 
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INFLAMMATORY PROFILE VERSUS RISK FACTORS 
In the present study the inflammatory markers hs-CRP, Total 
count, ESR and FFA were compared with various risk factors.  The levels 
of these markers were not found to vary significantly in smokers and 
alcoholic when compared with patients with nonsmokers/nonalcoholic. 
This is in contrast with the study conducted by Moghbeli66 N et al, where 
smokers with Acute coronary syndrome had higher CRP levels than non-
smokers (P<0.001).While comparing these inflammatory markers with 
DM and HTN only ESR found to be vary statistically significant manner 
(P=0.014). 
INFLAMMATORY PROFILE VERSUS ECG CHANGES 
In our present study the inflammatory markers were compared with 
various types of ECG changes between cases and controls. In these both 
hs-CRP and ESR were found to be vary significantly among the various 
ECG changes, hs-CRP with the P values <0.001 and for ESR with P 
values 0.031. This is in consistent with the study conducted by Srikanth 
.K. Sivaraman  96et al. 
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SUMMARY 
• There was significant correlation between AMI and Age, Sex, BP 
and BMI. 
• There was a significant correlation between AMI and the risk 
factors smoking and alcohol. 
• In the lipid profile TGL and HDL showed significant correlation 
with AMI while Total cholesterol and LDL did not show any 
statistical significance. 
• The values of hs-CRP were found to have highly significant 
correlation with AMI. 
• The other inflammations markers TC, ESR and FFA did not vary 
with statistical significance. 
• ESR and hs-CRP were found to have statistically significant 
correlation with various types of ECG changes. 
• There was no statistically significant correlation of inflammatory 
markers with regards to DM and HTN except ESR. 
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• The risk factors smoking and alcohol did not alter inflammatory 
profile significantly. 
• Elevation of hs-CRP can be used as adjuncts in the diagnosis of 
AMI. 
LIMITATIONS: 
• Only selected inflammatory markers were studied 
• Coronary artery disease not confirmed by angiogram. 
• Complications and follow up were not included in this study. 
• Cardiac enzymes could not be studied due to financial constraints. 
57 
 
CONCLUSIONS 
         Our study clearly indicated that hs-CRP is elevated in most of the 
cases of AMI and supporting the view that inflammation in the coronary 
vessels plays a very important role in the pathogenesis of AMI and other 
cardiac events. But AMI is not an overt inflammatory disease but events 
leading to AMI are every much influenced by the inflammatory process 
especially the plaque rupture. 
The hs-CRP measured by high sensitive assay is capable of 
detecting the ongoing inflammation in the coronary arteries. By 
considering hs-CRP as a diagnostic and therapeutic marker, added with 
the clear understanding of vascular biology, atherosclerosis and 
inflammation, our diagnostic and therapeutic methods will move in to 
new level in the management of CAD and AMI. 
The knowledge that atherosclerosis is an inflammatory disease, 
offers new opportunities for the prevention and management of CAD and 
AMI. However further evaluation and studies are required to clarify the 
exact roles played by these various inflammatory markers in the disease 
causation, progression and the therapeutic interventions. 
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Among the various inflammatory markers hs-CRP found to be 
highly significant and it can very well suggested to be a reliable 
diagnostic marker of inflammatory process in AMI, after excluding other 
condition which can produce elevation of hs-CRP.P 
 
 
 
 
 
 
ABBREVIATIONS 
ACS           Acute Coronary Syndrome 
AMI            Acute Myocardial Infarction 
AT-III                            Anti-Thrombin III 
ATP-III                          Adult Treatment Panel III 
AWMI                            Anterior Wall MI 
BMI                                Body Mass Index 
BP                                   Blood Pressure 
CAD                               Coronary Artery Disease 
CRP                               C- Reactive Protein 
DM                                 Diabetes Mellitus      
ECG                               Electrocardiogram 
ECHO                            Echocardiography 
ESR                                Erythrocyte Sedimentation Rate 
HDL                               High density Lipoprotein 
hs-CRP                          high sensitive C -Reactive Protein 
HT                                 Hypertension 
ICAM                           Intercellular Adhesion Molecule 
ICCU                            Intensive Coronary Care Unit       
IL                                  Interleukin 
IWMI                           Inferior Wall MI 
LDL                              Low Density Lipoprotein 
LT                                 Leukotriene 
LV                                Left ventricle 
MI                                 Myocardial Infarction 
MMP-9                         Matrix Metallo Proteinase-9 
MRFIT                         Multiple Risk Factor Intervention Trial 
NSTEMI                       Non ST  Elevation Myocardial Infarction 
PCI                                Percutaneous Coronary Intervention 
P value                          Probability value 
PR                                 Pulse Rate 
STEMI                          ST Elevation Myocardial Infarction 
SVCAM                        Soluble Vascular Cell Adhesion Molecule 
TC                                 Total Count 
UA                                 Unstable Angina 
VLDL                           Very LOW density Lipoprotein 
vWF                              von Willebrand Factor 
WBC                              White Blood Cell 
WHO                             World Health Organization 
  
MASTER CHART ABBREVIATIONS 
      
F                                     Female 
M                                    Male 
Risk F                            Smoking and Alcohol 
Risk G                           Diabetes and Hypertension 
BP                                  Blood pressure 
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PROFORMA 
 
Name of the patient : 
AID no   : 
Age    : 
Sex    : 
Address   : 
Symptomatology            
                                         Chest pain yes/no: 
                                          Dyspnoea yes/no: 
                                          Palpitations yes /no: 
                                          Syncope yes /no : 
                                          Sweating yes /no : 
Risk factors          
                                         H/O smoking   : 
 
                                         H/O alcohol consumption  : 
 
H/O hypertension   : 
 
                                         H/O diabetes                     : 
                     
Height   : 
Weight   : 
BMI    : 
Vitals 
Temperature                    : 
Pulse rate                         : 
Blood pressure  : 
 
Lipid profile  : 
 TGL   : 
 LDL   : 
 HDL   : 
 
Inflammatory profile        :     
 Hs CRP  : 
 Total count     : 
Free fatty acid  : 
 E    S  R           : 
 Obesity                  : 
 
Family history                  :  
Previous H/o angina         : 
ECG                                  : 
Chest X ray                       : 
 
Types of   AMI                : 
 
Acute AWMI                   : 
Acute   IWMI                   : 
Both AWMI and IWMI   : 
Extensive AWMI             : 
 
Echocardiogram             : 
 
 
 
 
 
 
  
 
